Review article · 2023 · Open access

Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review

Claudio Brasso, Gianluca Colli, Rodolfo Sgro, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni, Vincenzo Villari, Paola Rocca

Biomedicines, 11(3), 921 · Published 16 March 2023 · DOI 10.3390/biomedicines11030921

Open PDFView at the publisherCite this paper

In brief

“Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review” is a 2023 review article by Claudio Brasso and 7 co-authors, published in Biomedicines. OpenAlex counts 27 citations as of 20 November 2026, which puts it in the top 7% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at Biomedicines.

Citations
27
Most cited in
2026 (9)
Field-weighted impact
0.87
References
159
Authors
8

Abstract

Schizophrenia is among the fifteen most disabling diseases worldwide. Negative symptoms (NS) are highly prevalent in schizophrenia, negatively affect the functional outcome of the disorder, and their treatment is difficult and rarely specifically investigated. Serotonin-dopamine activity modulators (SDAMs), of which aripiprazole, cariprazine, brexpiprazole, and lumateperone were approved for schizophrenia treatment, represent a possible therapy to reduce NS. The aim of this rapid review is to summarize the evidence on this topic to make it readily available for psychiatrists treating NS and for further research. We searched the PubMed database for original studies using SDAM, aripiprazole, cariprazine, brexpiprazole, lumateperone, schizophrenia, and NS as keywords. We included four mega-analyses, eight meta-analyses, two post hoc analyses, and 20 clinical trials. Aripiprazole, cariprazine, and brexpiprazole were more effective than placebo in reducing NS. Only six studies compared SDAMs with other classes of antipsychotics, demonstrating a superiority in the treatment of NS mainly for cariprazine. The lack of specific research and various methodological issues, related to the study population and the assessment of NS, may have led to these partial results. Here, we highlight the need to conduct new methodologically robust investigations with head-to-head treatment comparisons and long-term observational studies on homogeneous groups of patients evaluating persistent NS with first- and second-generation scales, namely the Brief Negative Symptom Scale and the Clinical Assessment Interview for Negative Symptoms. This rapid review can expand research on NS therapeutic strategies in schizophrenia, which is fundamental for the long-term improvement of patients' quality of life.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Brasso, C., Colli, G., Sgro, R., Bellino, S., Bozzatello, P., Montemagni, C., Villari, V., & Rocca, P. (2023). Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review. Biomedicines, 11(3), 921. https://doi.org/10.3390/biomedicines11030921

MLA 9

Brasso, Claudio, et al. “Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review.” Biomedicines, vol. 11, no. 3, 2023, p. 921. https://doi.org/10.3390/biomedicines11030921.

Chicago

Brasso, Claudio, Gianluca Colli, Rodolfo Sgro, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni, Vincenzo Villari, and Paola Rocca. 2023. “Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review.” Biomedicines 11 (3): 921. https://doi.org/10.3390/biomedicines11030921.

Harvard

Brasso, C. et al. (2023) ‘Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review’, Biomedicines, 11(3), p. 921. doi:10.3390/biomedicines11030921.

IEEE

C. Brasso et al., “Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review,” Biomedicines, vol. 11, no. 3, p. 921, 2023, doi: 10.3390/biomedicines11030921.

BibTeX

@article{brasso2023efficacy,
  title     = {{Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review}},
  author    = {Brasso, Claudio and Colli, Gianluca and Sgro, Rodolfo and Bellino, Silvio and Bozzatello, Paola and Montemagni, Cristiana and Villari, Vincenzo and Rocca, Paola},
  journal   = {Biomedicines},
  year      = {2023},
  volume    = {11},
  number    = {3},
  pages     = {921},
  doi       = {10.3390/biomedicines11030921},
  url       = {https://doi.org/10.3390/biomedicines11030921}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202344
202477
202577
202699

Its field-weighted citation impact is 0.87: it has been cited 0.87 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • schizophrenia
  • negative symptoms
  • aripiprazole
  • cariprazine
  • brexpiprazole
  • lumateperone
  • antipsychotic drugs
  • treatment efficacy

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Brasso, C., Colli, G., Sgro, R., Bellino, S., Bozzatello, P., Montemagni, C., Villari, V., & Rocca, P. (2023). Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review. Biomedicines, 11(3), 921. https://doi.org/10.3390/biomedicines11030921

How many times has this paper been cited?

27 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Biomedicines: sign in and open the PDF from this page.

Who wrote this paper?

Claudio Brasso, Gianluca Colli, Rodolfo Sgro, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni, Vincenzo Villari, Paola Rocca.

What is the DOI of this paper?

10.3390/biomedicines11030921, permanently at https://doi.org/10.3390/biomedicines11030921. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.